Kalaris Therapeutics Business Summary

Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage biopharmaceutical company that generates value through the development and future commercialization of novel biologics for neovascular retinal diseases. The company’s business model is centered on the clinical advancement of its lead asset, TH103, with long-term revenue expected from product sales, strategic licensing, or milestone payments following regulatory approval. Kalaris operates primarily in the ophthalmology segment, focusing on high-prevalence conditions including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Within the competitive landscape, Kalaris contends with established incumbents like Regeneron (Eylea HD) and Roche (Vabysmo), as well as clinical-stage peers such as MeiraGTx and Annexon. Kalaris differentiates itself by positioning TH103 as a potential best-in-class therapy that utilizes a unique heparan sulfate proteoglycan (HSPG) anchoring mechanism to achieve superior intraocular durability and extended dosing intervals of four to six months. The company was founded by a distinguished group of industry veterans, including scientific co-founder Dr. Napoleone Ferrara—the Lasker Award-winning pioneer who discovered VEGF and invented Avastin and Lucentis—alongside Dr. Srinivas Akkaraju, Dr. Michael Dybbs, and Dr. Samir Patel. The leadership team is headed by President and CEO Andrew Oxtoby, formerly of Anneal Pharmaceuticals and Eli Lilly, and Chief Financial Officer Matthew Gall, who joined in late 2025 with a pedigree from iTeos Therapeutics and Sarepta. The Board of Directors is chaired by David Hallal, former CEO of Alexion Pharmaceuticals, and includes Audit Chair Leone Patterson. Kalaris is backed by a robust syndicate of institutional investors, including Samsara BioCapital, RTW Investments, Invus, and ADAR1 Capital Management, providing the capital necessary to fund operations through critical Phase 1b/2 clinical readouts expected in late 2026.